全文获取类型
收费全文 | 63936篇 |
免费 | 4491篇 |
国内免费 | 1389篇 |
专业分类
耳鼻咽喉 | 916篇 |
儿科学 | 1864篇 |
妇产科学 | 515篇 |
基础医学 | 4359篇 |
口腔科学 | 1133篇 |
临床医学 | 9183篇 |
内科学 | 15437篇 |
皮肤病学 | 212篇 |
神经病学 | 2274篇 |
特种医学 | 3332篇 |
外国民族医学 | 7篇 |
外科学 | 11953篇 |
综合类 | 8335篇 |
现状与发展 | 4篇 |
一般理论 | 4篇 |
预防医学 | 2867篇 |
眼科学 | 421篇 |
药学 | 4043篇 |
41篇 | |
中国医学 | 1231篇 |
肿瘤学 | 1685篇 |
出版年
2024年 | 127篇 |
2023年 | 1066篇 |
2022年 | 1701篇 |
2021年 | 2623篇 |
2020年 | 2613篇 |
2019年 | 2549篇 |
2018年 | 2414篇 |
2017年 | 2038篇 |
2016年 | 1892篇 |
2015年 | 2057篇 |
2014年 | 4214篇 |
2013年 | 4096篇 |
2012年 | 3286篇 |
2011年 | 3701篇 |
2010年 | 3006篇 |
2009年 | 2898篇 |
2008年 | 3129篇 |
2007年 | 3164篇 |
2006年 | 2780篇 |
2005年 | 2498篇 |
2004年 | 2085篇 |
2003年 | 1761篇 |
2002年 | 1508篇 |
2001年 | 1402篇 |
2000年 | 1119篇 |
1999年 | 1128篇 |
1998年 | 1013篇 |
1997年 | 965篇 |
1996年 | 757篇 |
1995年 | 701篇 |
1994年 | 627篇 |
1993年 | 523篇 |
1992年 | 554篇 |
1991年 | 438篇 |
1990年 | 411篇 |
1989年 | 327篇 |
1988年 | 322篇 |
1987年 | 290篇 |
1986年 | 298篇 |
1985年 | 298篇 |
1984年 | 289篇 |
1983年 | 203篇 |
1982年 | 226篇 |
1981年 | 177篇 |
1980年 | 137篇 |
1979年 | 104篇 |
1978年 | 84篇 |
1977年 | 54篇 |
1976年 | 53篇 |
1973年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
《European Urology Supplements》2015,14(1):9-11
The main goal in the management of patients with vesicoureteral reflux (VUR) is the preservation of kidney function by minimizing the risk of pyelonephritis. By defining and analyzing the risk factors for each patient depending on age, sex, grade of reflux, lower urinary tract dysfunction, anatomic abnormalities, and kidney status, it is possible to identify those patients with a potential risk of upper urinary tract infection and resulting renal scarring. This paper gives a brief overview of the European Association of Urology guidelines for the management and treatment of VUR in children. These guidelines are based on the best currently available knowledge and evidence. 相似文献
72.
Emmi Helle Aldo Córdova-Palomera Tiina Ojala Priyanka Saha Praneetha Potiny Stefan Gustafsson Erik Ingelsson Michael Bamshad Deborah Nickerson Jessica X. Chong University of Washington Center for Mendelian Genomics Euan Ashley James R. Priest 《Genetic epidemiology》2019,43(2):215-226
Loss of function variants in NOTCH1 cause left ventricular outflow tract obstructive defects (LVOTO). However, the risk conferred by rare and noncoding variants in NOTCH1 for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function NOTCH1 variants in 6% of individuals. Rare or low-frequency missense variants were found in 16% of families. To make a quantitative estimate of the genetic risk posed by variants in NOTCH1 for LVOTO, we studied associations of 400 coding and noncoding variants in NOTCH1 in 1,085 cases and 332,788 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO amongst European-ancestry individuals. This result was replicated in an independent analysis of 210 cases and 68,762 controls of non-European and mixed ancestry. In conclusion, carrying rare predicted loss of function variants in NOTCH1 confer significant risk for LVOTO. In addition, the two intronic variants seem to be associated with an increased risk for these defects. Our approach demonstrates the utility of population-based data sets in quantifying the specific risk of individual variants for disease-related phenotypes. 相似文献
73.
74.
75.
76.
77.
78.
79.
Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60–70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies.Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community.This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored. 相似文献
80.